GlassScriptPhysician profile
James E Mock
NPI 1417046822
$12,685.28
in general payments reported to CMS, 2019-2025
25 companies · $1,073 in 2025
The $1,073 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $83.09 · 2021: $8,701 · 2022: $2,060 · 2023: $405 · 2024: $53.50 · 2025: $1,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,531.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $7,928.81 | 2021 | |
| Bard Peripheral Vascular, INC. | $1,418.74 | 2022 | |
| Amgen INC. | $443.95 | 2022-2024 | Repatha |
| Abbott Laboratories | $417.19 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $344.75 | 2021-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $306.27 | 2019-2025 | |
| Pfizer INC. | $265.13 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $241.97 | 2021-2025 | Verquvo |
| Alnylam Pharmaceuticals INC. | $207.93 | 2025 | Amvuttra |
| Bridgebio Pharma, INC. | $191.35 | 2025 | Attruby |
| Philips North America LLC | $167.50 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $114.18 | 2021 | |
| Abiomed | $101.45 | 2021 | |
| Janssen Pharmaceuticals, INC | $88.62 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $88.46 | 2019-2025 | Farxiga |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $76.04 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $69.17 | 2025 | Lifevest |
| Cleerly, INC. | $49.55 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Kestra Medical Technology Services, INC. | $30.00 | 2025 | Assure Wcd |
| Boston Scientific Corporation | $29.55 | 2025 | Watchman Flx |
| Regeneron Healthcare Solutions, INC. | $26.67 | 2025 | Evkeeza |
| Edwards Lifesciences Corporation | $26.16 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.41 | 2025 | Jardiance |
| Novo Nordisk INC | $17.30 | 2025 | Wegovy |
| Kiniksa Pharmaceuticals, LTD. | $16.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.